SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.

In patients with T2D who had been hospitalized for poorly controlled blood glucose, SGLT2 inhibitors nearly doubled the risk ...

Topline data were announced from a phase 3 trial evaluating orforglipron in adults with T2D and inadequate glycemic control with diet and exercise alone.

Eligible participants were aged 50 and over, had a diagnosis of tT2D, and no prior history of dementia or use of ...

Menopause and the natural phenomenon of weight gain in middle age make this a topic for primary care physicians to watch.

In a study of adults with diabetes and gastrointestinal (GI) motility abnormalities, over 75% had GI motility abnormalities.

Among US adults without diabetes, the use of GLP-1 RAs increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022.

Millions of Medicaid beneficiaries have limited access to Type 2 diabetes medications that reduce the risk of cardiovascular disease, according to a study published April 22 in Annals of Internal ...

Duodenal mucosal resurfacing (DMR), a new-style endoscopic procedure using hydrothermal energy to ablate this thickened layer ...

A large population-based study found that GLP-1 receptor agonists (GLP-1RAs) and SGLT2 inhibitors (SGLT2is), two classes of ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Lilly trumpeted positive topline results from ACHIEVE-1 (NCT05971940) showing orforglipron to have met the trial’s primary ...